The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 2, 2006, Pages 107-114

  Mulder, Hans ^a,b   Herder, Anita ^c   Wilmink, Frederik W ^d   Tamminga, Wim J ^e   Belitser, Svetlana V ^a   Egberts, Antoine C G ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Wilhelmina Ziekenhuis   (Netherlands)

^c MARTINI HOSPITAL   (Netherlands)

^d GGZ Drenthe   (Netherlands)

^e PRA International USA   (Netherlands)

Author keywords

CYP2D6; Cytochrome P450 2D6; Genotype; Phamacogenetics; Therapeutic drug monitoring

Indexed keywords

9 HYDROXYRISPERIDONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450 2D6; DESVENLAFAXINE; DOXEPIN; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; NORCLOMIPRAMINE; NORDOXEPIN; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PERICIAZINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; VENLAFAXINE; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; CHRONIC PATIENT; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; FEMALE; FOLLOW UP; GENE DUPLICATION; GENETIC ANALYSIS; GENOTYPE; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; NORMAL VALUE; PHARMACOGENETICS; PRIORITY JOURNAL; REFERENCE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DRUG MONITORING; FEMALE; GENOTYPE; HOSPITALS, PSYCHIATRIC; HUMANS; INPATIENTS; LENGTH OF STAY; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NETHERLANDS; PHARMACOGENETICS; RETROSPECTIVE STUDIES;

EID: 33644621556     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1173     Document Type: Article

References (27)

1. Brockmoller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72: 438-452.
2. Dahl ML, Sjoqvist F. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther Drug Monit 2000; 22: 114-117.
3. Jaanson P, Marandi T, Kiivet RA, et al. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology 2002; 162: 67-73.
4. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-473.
5. Müller MJ, Dragicevic A, Fric M, et al. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry 2003; 36: 98-104.
6. Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit 2000; 22: 118-121.
7. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E. Relation between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 1997; 51: 395-398.
8. Meyer UA. pharmacogenetics and adverse drug reactions. The Lancet 2000; 356: 1667-1671.
9. Tamminga WJ, Werner J, Oosterhuis B, De Zeeuw RA, De Leij LF, Jonkman JH. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol 200 1; 57: 717-722.
10. Tamminga WJ, Wemer J, Oosterhuis B, et al. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study. Eur J Clin Pharmacol 2003; 59: 57-64.
11. Wolf CR, Smith NL, Smith G. Pharmacogenetics. Br Med J 2000; 320: 987-990.
12. Berecz R, De la rubia RA, Dorado P, Fernandez-Salguero P, Dahl ML, Llerena A. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol 2003; 59: 45-50.
13. Dahl ML. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002; 41: 453-470.
14. Grasmäder K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004; 60: 329-336.
15. Güzey G, Norstrom A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther Drug Monit 2002; 24: 436-437.
16. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173-192.
17. Köhnke MD, Griese EU, Stösser D, Gaertner I, Barth G. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 2002; 35: 116-118.
18. Pan L, Stichele RV, Belpaire FM. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentration of haloperidol and reduced haloperidol in schizophrenic inpatients. Ther Drug Monit 1999; 21: 489-497.
19. Ono S, Mihara K, Suzuki A, et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology 2002; 162: 50-54.
20. Mulder H, Wilmink FW, Beumer TL, Tamminga. WJ, Jedema JN, Egberts ACG. The association between Cytochrome P450-2D6 genotype and prescription patterns of antipsychotic and antidepressant drugs in hospitalised psychiatric patients: a retrospective follow-up study. J Clin Psychopharmacol 2005; 25: 188-191.
21. Stuven T, Griese EU, Kroemer HK, Eichelbaum M, Zanger UM. Rapid detection of CYP2D6 null alleles by long distance-and multiplex-polymerase chain reaction. Pharmacogenetics 1996; 6: 417-421.
22. Tamminga WJ, Werner J, Oosterhuis B, et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 1999; 55: 177-184.
23. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996; 392: 30-34.
24. Anonymous. Anatomical Therapeutic Chemical (ATC) Classification Index: including defined daily doses (DDDs) for plain substances. Oslo, Norway: World Health Organization 1997.
25. Pinheiro JC, Bates DM. Mixed-effects models in S and S-plus. Springer: Berlin, Heidelberg, New York, 2000.
26. Shao J, Tu D. The jackknife and bootstrap. Springer: Berlin, Heidelberg, New York, 1995.
27. Hiemke C, Dragicevic A, Grunder G, et al. Therapeutic Drug Monitoring of new antipsychotic drugs. Ther Drug Monit 2004; 26: 156-160.